Pharmacovigilance Literature Screening Services

Why literature monitoring sits at the center of drug safety

Marketing authorization holders are expected under Good Pharmacovigilance Practices (GVP) Module VI to monitor the worldwide scientific and medical literature for safety information on their products, and to do it on a defined, repeatable schedule. The volume is the problem. Relevant safety information is scattered across thousands of new articles each week, most of which are irrelevant to any one product, and a single missed case report can carry regulatory and patient-safety consequences. Screening that flood efficiently, without letting a genuine report slip through, is a methodology problem before it is a safety problem, and it is precisely the kind of high-recall, dual-reviewer screening our team performs every day for published systematic reviews.

Our angle is deliberately narrow and honest. Our pharmacovigilance literature screening services cover the surveillance and screening step: building the search, running it on your cadence, and flagging the articles that contain potential case or signal information for your safety team to action. We do not process individual cases, author periodic safety update reports, submit expedited reports to regulators, or act as your qualified person, because those are regulated safety functions that require qualified pharmacovigilance staff and a validated safety database. Keeping the scope to screening is exactly what lets us do that step rigorously, transparently, and cost-effectively.

What a valid case in the literature looks like

An article is relevant to safety surveillance when it describes enough for a reportable event: an identifiable patient, an identifiable reporter, a suspect medicinal product, and an adverse event or reaction. The screening criteria we agree with you translate those minimum elements, plus your product-specific terms and any signal or special-situation categories you monitor, into an explicit, testable checklist. Two reviewers then apply that checklist to every record, which is the difference between a defensible screen and a subjective one. Ambiguous articles, such as reviews that mention an event without a discrete case, are flagged for your team rather than silently excluded.

A transparent, dual-reviewer screening process

Every screen begins with a reproducible search strategy across the major biomedical databases, principally MEDLINE and Embase, documented well enough that another reviewer could rerun it and obtain the same records. The strategy captures the product and its active substance, relevant synonyms and brand names, and the date range, so coverage is explicit and auditable.

Two reviewers then screen titles, abstracts, and full text independently against the pre-specified criteria, with a third resolving any disagreement. This dual independent screening design is the single most important safeguard against a missed report, and it is the standard applied to every screening project, mirroring the two-reviewer requirement of the PRISMA reporting framework used in systematic reviews. Duplicate records retrieved from more than one database are removed with a documented deduplication step so nothing is double-counted and nothing is lost.

The screening runs through the same instrumented workflow as our systematic review work, so every inclusion and exclusion decision is logged with a timestamp and a reviewer. If you want to run the first pass yourself, our systematic review screening tool applies the same high-recall approach, and our methodologists take over for the full dual-reviewer screen and the documentation your standard operating procedures require.

Local and global literature, and the right cadence

Comprehensive surveillance usually needs both a global search of the major international databases and, where your obligations require it, a local search of regional and national journals in the relevant languages that the international databases do not index. We scope the coverage to your specific monitoring requirements and document exactly which sources were searched, over what period, and with what strategy.

Cadence is set to your obligations. Routine surveillance of a marketed product is often run weekly, while broader searches support periodic reporting, and a one-time historical search establishes a baseline for a new product or a new signal. Whatever the frequency, it is recorded in the methods trail so the schedule itself is auditable.

What you receive

You receive a documented, reproducible search strategy; a dual-reviewer screening record with every conflict resolved; a PRISMA flow diagram showing the number of records identified, screened, and included at each stage; and an extraction table of the relevant articles with the safety-relevant information clearly flagged for your safety team. The methods trail is written to align with your standard operating procedures, and monitoring runs on the schedule you set. You can build the flow figure from your own numbers with our PRISMA flow diagram generator, and structure the eligibility rules with our inclusion and exclusion criteria builder.

Quality control and the audit trail

Screening for drug safety is only as good as its documentation. Every project keeps a complete, reproducible record: the exact search strings, the databases and date ranges, the reviewer decisions, the conflict resolutions, and the deduplication log. That trail is what lets your team, or an inspector, reconstruct precisely how a given article was found and why it was included or excluded. Reproducibility is not an afterthought here; it is the deliverable.

Who runs your screen

The screen is designed and reviewed by PhD methodologists with formal training in evidence synthesis and search construction, the same specialists who build search strategies for published systematic reviews and who understand where a sensitive search gains or loses a relevant record. Screening for drug safety demands both a sensitive search, so nothing is missed, and disciplined criteria, so the safety team is not buried in noise. Balancing recall against precision is a methodology skill, and it is the reason clients bring their literature surveillance to a research methodology team rather than a general vendor.

You can see the full scope of our pharmacovigilance literature screening service for engagement models, cadence, and pricing. For adjacent evidence work, the same team delivers full our PhD-led systematic review service and literature review writing, so a screening engagement can extend naturally into a structured evidence review or a benefit-risk literature assessment when your safety or regulatory question calls for one.